Purpose Targeted delivery of alpha-particle-emitting radionuclides is a promising novel option in cancer therapy. We generated stable conjugates of the vascular tumour-homing peptide F3 both with 
Introduction
Targeted delivery of alpha-particle-emitting isotopes such as 225 Ac, 213 Bi, 212 Bi/ 212 Pb, 211 At or 227 Th is a promising new option in cancer therapy. A number of studies have been conducted in preclinical models providing evidence that conjugates of such radionuclides with antibodies or peptides are effective in treatment of tumour xenografts of prostate [1, 2] , ovarian [3, 4] , breast [5] [6] [7] , bladder [8] , colon [9] and gastric [10, 11] cancer, as well as in lymphoma [12, 13] and somatostatin receptor-positive pancreatic tumours [14, 15] . Other possible future applications of α-emitter conjugates include killing of tumour neovasculature [16] and nonmyeloablative conditioning for haematopoietic stem cell transplantation [17] . Moreover, clinical trials using α-emitter antibody or peptide conjugates that specifically bind to cancer cells have revealed modest but encouraging results in the treatment of melanoma [18] , gliomas [19, 20] , acute myeloid leukaemia [21] and ovarian carcinoma [22] .
Among the α-emitters used for targeted therapy so far, 213 Bi (t 1/2 46 min) and 212 Bi (t 1/2 60.6 min) have the shortest physical half-lives. Such short-lived radionuclides might affect the efficacy of targeted therapy, particularly after systemic administration, because the time could be too short to allow saturation of tumour targets before the majority of the activity has decayed [23] . To optimize therapeutic efficacy it has been suggested that α-emitters with substantially longer half-lives be used such as 225 Ac (t 1/2 10 days) [24] . Today the method of choice for production of 225 Ac is radiochemical separation from 229 Th, available from the decay of 233 U [25] . To increase the availability of 225 Ac which currently amounts to 60 GBq/ year, alternative methods such as proton irradiation of a 226 Ra target in a cyclotron have been developed [26] . In the course of the decay of 225 Ac four α-particles are released compared to only one α-particle originating from the 213 Bi decay chain. Thus, targeted alpha therapy using 225 Ac has been reported as much more potent than that using 213 Bi [6, 24] . On the other hand, stable coupling of 225 Ac together with its α-particleemitting daughter nuclides 221 Fr, 217 At, and 213 Bi to antibodies or peptides is not possible with the chelating compounds currently available. The decay of 225 Ac to 221 Fr releases a recoil kinetic energy significantly greater than the chemical bond energies of any chelating agent, resulting in loss of the daughter nuclide from the chelate molecule [23] . Therefore, if 225 Ac does not decay within a tumour cell, the daughter radionuclides might spread in the circulation causing toxic side effects. In order to develop novel cancer therapies, it is important to compare the different antitumour and potential toxic effects of constructs labelled with 225 Ac or 213 Bi and to define therapeutic windows for both isotopes.
F3 is a vascular tumour-homing peptide of 32 amino acids that binds specifically to nucleolin on the surface of tumour and tumour endothelial cells. In resting cells, nucleolin is primarily expressed in the nucleus. In contrast, in proliferating tumour or tumour endothelial cells, nucleolin is cyclically transported from the nucleus to the cell surface and back by a specific shuttle mechanism. Therefore, nucleolin is potentially an appropriate target for selective tumour therapies. Indeed, it has been reported that F3 is capable of transporting nanoparticles or fluorescent dyes such as FITC into the nuclei of tumour cells and tumour endothelial cells in vitro and in vivo [27] . F3 is also a highly effective carrier molecule for alpha-emitters because internalization into the nucleus of tumour cells enhances the probability for induction of DNA double-strand breaks by α-particles [28] . We recently discussed a radioconjugate of F3 that may be useful in tumour therapy: 213 Bi-DTPA- [F3] 2 , a dimer of F3 linked to DTPA, that forms stable complexes with 213 Bi. Just like F3, 213 Bi-DTPA- [F3] 2 is internalized into the nucleus of tumour cells upon binding, enhancing the cytotoxic effect of 213 Bi. The conjugate specifically accumulates in tumour tissue in vivo and consequently interferes with growth of small tumours and reduces the size of advanced tumours in a preclinical model of peritoneal carcinomatosis, thus leading to prolonged survival of animals [5] . Furthermore, conjugates of the α-emitter 225 Ac coupled to F3 exactly meet the demands of the proposed atomic nanogenerator releasing four α-particles in the course of 225 Ac decay within a tumour cell [24] . We have generated stable conjugates of F3 with 225 Ac ( 225 Ac-DOTA-F3) and 213 Bi ( 213 Bi-DTPA-F3) and have compared the cytotoxicity and therapeutic efficacy of the two radioconjugates in a mouse model of peritoneal carcinomatosis. We have also analysed histologically possible differences in the toxic side effects after intraperitoneal therapy with both 225 Ac-DOTA-F3 and 213 Bi-DTPA-F3.
Materials and methods

Radiochemistry and peptide labelling
The F3 peptide with 32 amino acids was synthesized and conjugated with either DOTA (3, 213 Bi generator system (Institute for Transuranium Elements, Karlsruhe, Germany) with a solution of 0.1 M HCl and 0.1 M NaI. The 213 Bi eluate ions (37-148 MBq in 600 μl) were then buffered with 3 M NH 4 Ac (100 μl) and with 40 mg/ml ascorbic acid (100 μl) to pH 5.5. After addition of 5-20 μg F3 (10 μl), the reaction was continued for 7 min at room temperature. The radiolabelled peptides were used without further purification. The binding percentages of 225 Ac to DOTA-F3 and of 213 Bi to DTPA-F3 were determined by instant thin-layer chromatography using silica gel-impregnated glass fibre sheets (Pal Gelman Laboratory, Ann Arbor, MI) as the stationary phase and 0.05 M tri-sodium citrate (pH 5.5) as the mobile phase. The activities of unbound 225 Ac/ 213 Bi (top) and 225 Ac/ 213 Bi bound to DOTA-F3/DTPA-F3 (bottom) on the chromatography strips were quantified using a gamma-counter.
Cell culture and clonogenic assay
The nucleolin-expressing tumour cell line EMT6 was grown in Waymouth medium (Gibco) supplemented with 10% fetal calf serum (Biochrom, Berlin, Germany) and penicillin (100 U/ml)/streptomycin (0.1 mg/ml 4 cells were then mixed with 0.7% low melting agarose in 3 ml cell culture medium. 1.5 ml of this suspension was placed in the wells of a sixwell plate and covered with base agar. Cell culture dishes were then incubated at 37°C for 1-2 weeks and subsequently stained with 0.5 ml 0.005% cresyl violet solution for 1 h. Colonies were counted using an inverted microscope (Zeiss, Oberkochen, Germany).
Xenograft model of peritoneal carcinomatosis SCID mice (Charles River, Sulzfeld, Germany) were injected intraperitoneally with 1×10 7 MDA-MB-435 cells expressing firefly luciferase in 100 μl phosphate-buffered saline (PBS). For monitoring of therapeutic efficacy groups of eight mice each were injected every second or third day with 1.85 MBq 213 Bi-DTPA-F3 or with 1.85 kBq 225 Ac-DOTA-F3 or 100 μl PBS between day 15 and 27 after inoculation of the tumour cells (Fig. 1) . The health and weight of the animals were monitored daily. Animals showing signs of weakness or distress were killed. The level of statistical significance with regard to survival was set at p< 0.05. The animal experiments were approved and supervised by the government of Upper Bavaria.
Bioluminescence imaging
Bioluminescence imaging was performed as described previously [5] . Briefly, animals were anaesthetized by intraperitoneal injection of 10 μl/g body weight of anaesthetic solution comprising 10% Ketavet (Pharmacia & Upjohn, Erlangen, Germany), 8% Rompun (Bayer, Leverkusen, Germany) and 82% 0.9% NaCl. Simultaneously, D-luciferin (300 μl, 15 mg/ml; Synchem, Germany) was injected intraperitoneally. Imaging was performed 10 min after injection using a cooled CCD camera (Hamamatsu, Herrsching, Germany). The time-points for bioluminescence imaging in the therapy groups were from day 14 to day 85 after inoculation of tumour cells, as indicated in Fig. 1 .
Histological procedures and immunohistochemistry
Organs (heart, liver, lung, spleen, adrenal gland, brain and kidneys) of animals that had to be killed after therapy with 225 Ac-DOTA-F3 or 213 Bi-DTPA-F3 were fixed in 4% buffered formalin and embedded in paraffin. Slices of thickness 4 μm were stained with haematoxylin and eosin (H&E), periodic acid Schiff (PAS) or Elastica van Giessen (EvG). For immunohistochemical analysis, 1-μm thick paraffin slices were dewaxed and rehydrated. The sections were incubated with primary antibodies (dilution 1:100 each) for 2 h at room temperature. All primary antibodies were purchased from Abcam (Cambridge, UK). For verification of antibody binding a Universal DAB Detection Kit (Roche-Ventana) and DAB (3,3-diaminobenzidine tetrahydrochloride) were used. The kit utilizes a cocktail of secondary antibodies labelled with horseradish peroxidase. Immunohistochemistry was performed using the CC1 program of the automated immunostainer Discovery XT (Roche-Ventana). Images were acquired using an Olympus Dotslide virtual microscope system (version 2.0).
Morphometric analysis
The morphometric analysis was performed using Definiens Tissue Studio software. In brief, the images were imported, ROIs were defined manually, and a predefined rule set was used to calculate the area of necrosis, the DAB-positive nuclei and the DAB-positive endothelial lining. The data were exported to Excel for further statistical analysis.
Results
Radiolabelling and comparison of antitumour activity of 213 Bi-DTPA-F3 and 225 Ac-DOTA-F3 in vitro
The labelling yields of concentration reducing the number of clones by 50% compared to controls, could be estimated. The ID 50 values of 213 Bi-DTPA-F3 and 225 Ac-DOTA-F3 were determined as 53 kBq/ml and 67 Bq/ml, respectively. This indicates that under these experimental conditions with a 24-h incubation period the antitumour efficacy of 225 Ac-DOTA-F3 is approximately 1,000-fold higher than that of 213 Bi-DTPA-F3 in terms of the total applied activity concentration (data not shown). It should be noted that during the 24-h incubation period, short-lived 213 Bi would have completely decayed, while only 6.7% of 225 Ac would have decayed.
Treatment of peritoneal carcinomatosis with 225 Ac-DOTA-F3 or 213 Bi-DTPA-F3
As we found in vitro that the cytotoxicity of 225 Ac-DOTA-F3 was approximately 1,000-fold higher than that of 213 Bi-DTPA-F3 in the clonogenic assays, we next tested the antitumour activity of both compounds in vivo. The activity of 213 Bi-DTPA-F3 for fractionated alpha therapy was calculated according to the MTD for 213 Bi-DTPA-F3 (11.1 MBq, unpublished) and previous studies using 213 Bi-d9MAb [11] and 213 Bi-DTPA-[F3]2 [5] . SCID mice bearing intraperitoneal MDA-MB-435-luc tumour xenografts were treated with six intraperitoneal injections of 1.85 kBq 225 Ac-DOTA-F3 or with six intraperitoneal injections of 1.85 MBq 213 Bi-DTPA-F3 administered every second or third day (Fig. 1) . The median survival of the mice in the control group treated with intraperitoneal injections of PBS was approximately 60 days. The median survival in the groups treated with 225 Ac-DOTA-F3 and 213 Bi-DTPA-F3 was 95 days and 97 days, respectively (Fig. 2) . These data indicate that both constructs significantly improved survival of mice with peritoneal carcinomatosis compared to the control group. However, statistical analysis did not reveal a significant difference in the survival of mice treated with 225 Ac-DOTA-F3 or with 213 Bi-DTPA-F3. The results further suggest that the 225 Ac-labelled peptide also has a 1000-fold higher antitumour activity than the 213 Bi-labelled peptide in vivo.
Monitoring of tumour development by bioluminescence imaging
Although there was no significant difference in overall survival after treatment with either 213 Bi-DTPA-F3 or Bi-DTPA-F3 were injected intraperitoneally six times from day 15 (D15) to day 27 (D27) after tumour cell inoculation. Bioluminescence imaging was performed weekly or biweekly from day 14 (D14) to day 85 (D85) growth as determined by bioluminescence imaging. Tumour imaging was performed 1 day before the start of treatment, i.e. 14 days after tumour cell inoculation, and thereafter once weekly or biweekly over approximately 100 days. The imaging schedule is shown in Fig. 1 . In the control group treated with PBS, the tumour mass linearly increased until the animals were killed. In contrast, in mice treated with 213 Bi-DTPA-F3, the tumour mass initially increased until 1-8 days after the last treatment (days [28] [29] [30] [31] [32] [33] [34] [35] and then declined until a minimum was reached 29 days after the last treatment (day 56; Fig. 3a) . After that, the tumour mass slowly increased again, finally causing the death of the animals. In animals treated with 225 Ac-DOTA-F3, the tumour mass increased in spite of treatment until 8-22 days after the last treatment (days 35-49), but then gradually decreased (Fig. 3a) . Nevertheless, the animals had to be killed due to increasing distress. These results were confirmed by quantification of the bioluminescence signals (Fig. 3b) . Death of the animals might finally have been caused by metastasis of small tumour nodules that escaped the treatment inducing internal haemorrhage of the aorta combined with the development of ascites.
Histological and immunochemical analysis of intraperitoneal tumours after treatment with 213 Bi-DTPA-F3 or 225 Ac-DOTA-F3
H&E-stained sections of xenograft tumours after treatment showed a consistent picture with map-like necrosis, highly basophilic debris deposits in the necrosis centre, a rim consisting of shrunken nuclei and vital tumour parts. The Ac-DOTA-F3 (mouse 5 and 6) between day 15 (D15) and day 27 (D27) after tumour cell inoculation. b Two mice (mouse 3 and mouse 6) were selected randomly from each treatment group for bioluminescence imaging and the bioluminescence signals (ROI over the tumours) were analysed quantitatively cytology of the tumour cells was uniform with large nuclei, a prominent nucleolus and slight basophilic cytoplasm; mitotic cells were frequently present. No obvious differences in tumour composition, necrosis fraction or size were observed in the tumours after treatment with 213 Bi-DTPA-F3 or 225 Ac-DOTA-F3. Quantitative assessment of the tumour sections using Definiens TissueMap software revealed that the necrosis fractions in tumours treated with 225 Ac-DOTA-F3, 213 Bi-DTPA-F3 and PBS were 43%, 36% and 5%, respectively (Fig. 4a, b) . Quantification of the percentages of apoptotic cells present in tumours by immunostaining using anticaspase-3 antibody revealed increased numbers of apoptotic cells after treatment with 225 Ac-DOTA-F3 or 213 Bi-DTPA-F3 compared to that after PBS treatment. However, the percentage of apoptotic cells was only 1/40th that of necrotic cells (Fig. 4b) . Interestingly, the animals treated with 213 Bi-DTPA-F3 showed fewer peritoneal metastases than those treated with 225 Ac-DOTA-F3 (Fig. 4c ).
Histological analysis of renal pathology after 213 Bi-DTPA-F3 and 225 Ac-DOTA-F3 treatment
As reported recently, radiolabelled F3 peptide accumulates selectively in tumour tissue but also in the kidneys due to renal excretion [5] . Therefore, toxic side effects to the kidneys of therapy with 213 Bi-DTPA-F3 ( Fig. 5e-h ) and 225 Ac-DOTA-F3 ( Fig. 5a-d) are to be expected. We analysed the renal pathology upon treatment with the two compounds. H&E staining of kidney slices of animals treated with 225 Ac-DOTA-F3 showed acute necrosis in 17% of the cortical tubuli (especially in the outer cortical areas), detached highly eosinophilic epithelia, focal necrotic cells and focal vacuolated epithelial cells. Oedema was present in 20% of tubuli (Fig. 5a, b) . Regenerative changes in tubule epithelia were observed to a minor degree (0-2% of tubuli). Both H&E and PAS staining revealed only negligible protein casts (<1%) indicative of mild nephrotoxicity (Fig. 5c) . This finding was supported by the absence (<1%) of fibrosis (scar formation) shown by the EvG stain ( Fig. 5d; Table 1 ). In the 213 Bi-DTPA-F3-treated animals, 15% of the cortical tubuli showed acute necrosis and 15% of the tubuli showed epithelial oedema. The extent of inflammatory cell infiltrates was only weak (<1%). Regenerative changes in the epithelial cells due to cellular damage were seen in 5% of tubuli (Fig. 5e, f) . Neither PAS nor EvG staining revealed protein casts or scar formation ( Fig. 5g, h ; Table 1 ).
Discussion
Targeted therapy with radionuclides as cytotoxic compounds has been successfully applied using both peptides and antibodies as carrier molecules. Radiolabelled peptides targeting receptor molecules overexpressed on tumour cells include ligands (or antagonists) of the somatostatin receptor [29, 30] , the cholecystokinin 2/gastrin receptor, the glucagon-like peptide-1 receptor, the neurokinin type-1 receptor, the neurotensin receptor and the gastrin-releasing peptide receptor, to name just a few [20, 31] . Radionuclides targeted with antibodies have been administered in numerous tumours showing overexpression or exclusive expression of tumour surface antigens [32] [33] [34] . Radionuclides used for targeted therapy predominantly include β-emitters such as 131 I, 177 Lu and 90 Y due to their good availability and ease of handling. However, the α-emitters 225 Ac and 213 Bi have turned out to be superior to the β-emitters 177 Lu and 90 Y in prostate, breast and gastric cancer models of targeted therapy with regard to therapeutic efficacy [2, 6] and toxicity [35] . Therefore α-emitters have received increasing attention in spite of problems of availability. Because the α-emitters currently under investigation ( 225 Ac, 211 At, 212 Bi, 213 Bi, 227 Th) differ in their physical properties, comparison of the therapeutic efficacy and toxicity of different α-emitters is of particular interest.
The 225 Ac-labelled anti-HER-2/neu monoclonal antibody (7.16.4) has been found to be significantly more effective than 213 Bi-labelled 7.16.4 in a mouse model of breast cancer metastases [6] . Radioimmunoconjugates composed of the anti-CD45 antibody 30F11 and 211 At targeting haematopoietic tissues are more effective in inducing myeloablation and less toxic than the corresponding 213 Bi conjugates [17] . The aim of our study was to compare the therapeutic efficacy and toxicity of 225 Ac-DOTA-F3 and 213 Bi-DTPA-F3 targeting nucleolin in a breast cancer model of peritoneal carcinomatosis. We found that 225 Ac-DOTA-F3 has an approximately 1,000-fold higher antitumour activity in vitro and in vivo. Both conjugates improved survival of treated animals and reduced tumour mass. Median survival significantly increased to 97 and 95 days after repeated therapy (six times) from day 15 to day 27 after tumour cell inoculation with 213 Bi-DTPA-F3 (1.85 MBq) or 225 Ac-DOTA-F3 (1.85 kBq), respectively. As the physical half-life of 225 Ac-DOTA-F3 (10 days) is markedly longer than that of 213 Bi-DTPA-F3 (46 min), the effect of 225 Ac occurred later and was more prolonged than that of 213 Bi, but final survival rates were not significantly different between the two groups. Our finding that 213 Bi-DTPA-F3 was more effective in reducing the number of peritoneal metastases is also most likely due to the different half-lives of the two radionuclides. 213 Bi exerts its antitumour effect at early time-points when relatively small tumour nodules are present that can be completely eliminated by treatment. In contrast, 225 Ac exerts its effect over a longer time period, presumably leading to reduced growth rather than to complete elimination of metastases. The retarded therapeutic efficacy of In a mouse model of breast cancer pulmonary metastases, a single treatment with 225 Ac-anti-HER-2/neu immunoconjugates (14.8 kBq) was significantly more effective than treatment with the corresponding 213 Bi immunoconjugates (4.44 MBq) [6] . Therapeutic efficacy was dependent both on the timing of the treatment and the applied activity: administration of immunoconjugates 3 days after tumour cell injection was significantly more effective than administration 18 days after tumour cell injection. Treatment with 14.8 kBq 225 Ac-anti-HER-2/neu significantly increased survival compared to 7.4 kBq [6] . Therefore, to improve therapeutic efficacy in our intraperitoneal breast cancer model, early administration of higher activities of 225 Ac-DOTA-F3 could be beneficial.
Nevertheless, therapeutic efficacy has to be balanced with toxic side effects caused by administration of α-emitter conjugates. In the study presented here histological analysis of the kidneys revealed only minor nephrotoxicity of both conjugates. Moreover, toxicity of 225 Ac-DOTA-F3 seemed to be only slightly more pronounced (Table 1) . There are two possible explanations for these surprising results concerning toxicity. First, as both F3 conjugates are excreted by the kidneys radioactivity not bound to tumour or tumour endothelial cells is rapidly eliminated within hours. As 225 Ac has a half-life of 10 days, within this time-frame only a minor but constant dose is delivered to the kidney. In contrast, 213 Bi has a half-life of approximately 46 min. As reported recently, up to 40% of the injected dose is present in the kidney within the first hours after injection of F3 [5] . Therefore, a relatively high dose is delivered to this organ in a short time interval. Second, as F3 is internalized only in proliferating cells, it is possible that it has only minor effects on the quiescent renal tubular cells. Nevertheless, side effects may still become apparent at later time-points as the follow-up period was only 100 days. As has been found in a previous study, the general renal parenchymal architecture was preserved at 10 weeks after injection of Ac-225-HuM195. Severe renal damage was not observed until 20 and up to 40 weeks after injection [36] .
Long-term severe renal toxicity was observed after successful therapy of pulmonary metastases in a mouse breast cancer model using 225 Ac-anti-HER-2/neu immunoconjugates (14.8 kBq) [6] . At 1 year after treatment no lung metastases were found, but in the kidney cortex loss of tubular epithelium and in the kidney medulla loss of tubules were detected, most probably due to kidney retention of the 225 Ac daughter nuclides 221 Fr and 213 Bi [6] . 221 Fr is released from the immunoconjugate because the recoil energy in the course of 225 Ac decay is significantly greater than the chemical bond energy of any chelating agent. Following intravenous injection of 225 Ac-huM195 immunoconjugates (22.2 kBq) into tumour-free mice the absorbed dose estimates were 15 Gy to the renal cortex and 23 Gy to the renal medulla. Almost 80% (18.2 Gy) of the estimated absorbed dose to the renal medulla was delivered by free 213 Bi generated by extrarenal decay of 225 Ac [23] . Therefore, the overall success of 225 Ac radioimmunotherapy is largely dependent on methods to reduce renal accumulation of the α-particle-emitting daughter nuclides 221 Fr and 213 Bi. Radiation nephropathy after intravenous injection of 225 AchuM195 could be mitigated by the aldosterone receptor antagonist spironolactone and, to a lesser extent, by the angiotensin receptor-1 blocker L-158,809 [37] . Moreover, metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade might be successful strategies to attenuate the renal accumulation of 225 Ac daughter nuclides [38] . 213 Bi are partially retained within the nanoparticles and thus retention of the daughter nuclides in the target organ is increased [39] .
Another interesting finding of our study was that the mechanism by which both 225 Ac-DOTA-F3 and 213 Bi-DTPA-F3 induced cell death was predominantly necrosis, as approximately 40% of the tumour mass was found to be necrotic after treatment. In contrast, the proportion of apoptotic cells was lower than 1%. This result is in line with previous findings according to which 213 Bi-anti-d9-E-cadherin immunoconjugates induced necrosis but not apoptosis in the gastric cancer cell line HSC45-M2 [40, 41] . Predominant induction of necrosis compared to apoptosis by 225 Ac-DOTA-F3 and 213 Bi-DTPA-F3 might have been because of the high activities administered. It is possible that apoptosis is the primary mechanism of cell death upon treatment with lower activities inducing less severe cellular damage (DNA double strand breaks).
Although it is still a matter of debate which isotope is more appropriate for use in cancer therapy, our data indicate that 225 Ac is a promising candidate. To enhance therapeutic efficacy of 213 Bi-DTPA-F3 additional administrations between days 35 and 56 after tumour cell inoculation could improve the outcome. Another promising option is treatment of tumours with a combination of different α-particle-emitting conjugates. As has been demonstrated recently, combined administration of 213 Bi immunoconjugates targeting two distinct molecules on colon cancer cells (TAG- 72 and HER-2) resulted in enhanced therapeutic benefit [9] . Likewise, coadministration of 213 Bi-DTPA-F3 and 225 Ac-DOTA-F3 might be advantageous in therapy of peritoneal carcinomatosis because the immediate antitumour effect of 213 Bi would be combined with the long-term growth inhibition of 225 Ac. Because chemotherapy has turned out to be largely insufficient for the treatment of peritoneal carcinomatosis, new treatment options are urgently needed. Conjugates of the tumour-homing peptide F3 targeting nucleolin coupled with the α-particle-emitting radionuclides 225 Ac or 213 Bi are rapidly transported to the nucleus thus irreversibly damaging nuclear DNA. In a mouse peritoneal carcinomatosis model both 225 Ac-and 213 Bi-F3 conjugates significantly prolonged survival without causing severe toxic side effects. These results suggest that further studies are justified to test the potential of 225 Ac and 213 Bi for use in humans.
